A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

BACKGROUND: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. In order to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tantai, Narisa, Chaikledkaew, Usa, Tanwandee, Tawesak, Werayingyong, Pitsaphun, Teerawattananon, Yot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996169/
https://www.ncbi.nlm.nih.gov/pubmed/24731689
http://dx.doi.org/10.1186/1472-6963-14-170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996169/
https://www.ncbi.nlm.nih.gov/pubmed/24731689
http://dx.doi.org/10.1186/1472-6963-14-170

Ejemplares similares